2025. Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s707. DOI:https://doi.org/10.25251/fpf9fe87.